DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Dr. Lal Path Labs Ltd. — Press Release

NSE 1 hr ago·4 Nov 2026, 8:46 am

Dr. Lal Path Labs

Dr. Lal Path Labs has announced its un-audited financial results for the quarter and half-year ended September 30, 2026. The company has submitted this information to the stock exchanges, providing a snapshot of its performance during this period.

For investors, this update is a key indicator of the diagnostic services provider's operational health. It offers insights into revenue trends, profitability, and the company's ability to manage costs, which are critical factors for assessing its future growth potential.

Investors should focus on the specific figures for net profit and revenue growth. Comparing these numbers with previous quarters and industry benchmarks will help in understanding the company's current trajectory and market position.